Salivary Osteopontin Was Associated with Lesion Size in Patients with Oral Lichen Planus
,
Abstract
Introduction: Osteopontin (OPN) is recognized as a potent biomarker of Oral lichen planus (OLP) because of its vital role in inflammation and the repair process. The present study aims to assess OPN in OLP in comparison with healthy controls (HC). Materials and Methods: To explore salivary levels of OPN, a group of 20 subjects with OLP was compared with 20 healthy controls. Salivary OPN levels were measured by enzyme-linked immunosorbent (ELISA) assay.Results: Results indicated elevated OPN levels in lesion size<1cm compared with 1-3cm lesion size of OLP (p=0.02). In contrast, we did not find a significant difference in OPN expression level in saliva from OLP patients and healthy controls (P=0.96). Conclusion: Osteopontin plays a role in the process of repair and healing in oral lichen planus, providing tissue protection and enhancing the capacity for tissue wound healing in these lesions. Keywords: Oral lichen planus; Osteopontin; Saliva.
1. Müller S. Oral lichenoid lesions: distinguishing the benign from the deadly. Mod Pathol 2017;30:S54–67.
2. Roopashree MR, Gondhalekar RV, Shashikanth MC, George J, Thippeswamy SH, Shukla A. Pathogenesis of oral lichen planus--a review: Pathogenesis of oral lichen planus. J Oral Pathol Med 2010;39:729–34.
3. Talungchit S, Buajeeb W, Lerdtripop C, Surarit R, Chairatvit K, Roytrakul S, et al. Putative salivary protein biomarkers for the diagnosis of oral lichen planus: a case-control study. BMC Oral Health 2018;18:42.
4. Al-Hashimi I, Schifter M, Lockhart PB, Wray D, Brennan M, Migliorati CA, et al. Oral lichen planus and oral lichenoid lesions: diagnostic and therapeutic considerations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103 Suppl:S25.e1-12.
5. Fitzpatrick SG, Hirsch SA, Gordon SC. The malignant transformation of oral lichen planus and oral lichenoid lesions: a systematic review. J Am Dent Assoc 2014;145:45–56.
6. Sugerman PB, Savage NW, Walsh LJ, Zhao ZZ, Zhou XJ, Khan A, et al. The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med 2002;13:350–65.
7. Cristaldi M, Mauceri R, Di Fede O, Giuliana G, Campisi G, Panzarella V. Salivary biomarkers for oral squamous cell carcinoma diagnosis and follow-up: Current status and perspectives. Front Physiol 2019;10:1476.
8. Blanco BA, Wolfgang CL. Liquid biopsy for the detection and management of surgically resectable tumors. Langenbecks Arch Surg 2019;404:517–25.
9. van Bilsen JHM, van den Brink W, van den Hoek AM, Dulos R, Caspers MPM, Kleemann R, et al. Mechanism-based biomarker prediction for low-grade inflammation in liver and adipose tissue. Front Physiol 2021;12:703370.
10. Zhou Z-T, Wei B-J, Shi P. Osteopontin expression in oral lichen planus: Osteopontin expression in oral lichen planus. J Oral Pathol Med 2008;37:94–8.
11. Lu R, Zhang J, Sun W, Du G, Zhou G. Inflammation-related cytokines in oral lichen planus: an overview. J Oral Pathol Med 2015;44:1–14.
12. Rhodus NL, Ho V, Miller CS, Myers S, Ondrey F. NF-kappaB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detect Prev 2005;29:42–5.
13. Pekiner FN, Demirel GY, Borahan MO, Ozbayrak S. Cytokine profiles in serum of patients with oral lichen planus. Cytokine 2012;60:701–6.
14. Abboud CS, Brandão EH da S, Cunha KRL, de Sousa Brito K, Gallo C de B, Molon AC, et al. Serum and salivary cytokines in patients with oral lichen planus treated with Photobiomodulation. Oral Dis 2023;29:1250–8.
15. Simark-Mattsson C, Bergenholtz G, Jontell M, Eklund C, Seymour GJ, Sugerman PB, et al. Distribution of interleukin-2, -4, -10, tumour necrosis factor-alpha and transforming growth factor-beta mRNAs in oral lichen planus. Arch Oral Biol 1999;44:499–507.
16. Kadry D, Rashed L. Plasma and tissue osteopontin in relation to plasma selenium in patients with psoriasis: Osteopontin and selenium in psoriasis. J Eur Acad Dermatol Venereol 2012;26:66–70.
17. Buback F, Renkl AC, Schulz G, Weiss JM. Osteopontin and the skin: multiple emerging roles in cutaneous biology and pathology. Exp Dermatol 2009;18:750–9.
18. Subraman V, Thiyagarajan M, Malathi N, Rajan ST. OPN -revisited. J Clin Diagn Res 2015;9:ZE10-3.
19. O’Regan AW, Nau GJ, Chupp GL, Berman JS. Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks. Immunol Today 2000;21:475–8.
20. Icer MA, Gezmen-Karadag M. The multiple functions and mechanisms of osteopontin. Clin Biochem 2018;59:17–24.
21. Denhardt DT, Noda M, O’Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001;107:1055–61.
22. Gebri E, Kiss A, Tóth F, Hortobágyi T. Salivary osteopontin as a potential biomarker for oral mucositis. Metabolites 2021;11:208.
23. Sodek J, Batista Da Silva AP, Zohar R. Osteopontin and mucosal protection. J Dent Res 2006;85:404–15.
24. Santarelli A, Mascitti M, Rubini C, Bambini F, Zizzi A, Offidani A, et al. Active inflammatory biomarkers in oral lichen planus. Int J Immunopathol Pharmacol 2015;28:562–8.
25. hang Y, Lin M, Zhang S, Wang Z, Jiang L, Shen J, et al. NF-kappaB-dependent cytokines in saliva and serum from patients with oral lichen planus: a study in an ethnic Chinese population. Cytokine 2008;41:144–9.
2. Roopashree MR, Gondhalekar RV, Shashikanth MC, George J, Thippeswamy SH, Shukla A. Pathogenesis of oral lichen planus--a review: Pathogenesis of oral lichen planus. J Oral Pathol Med 2010;39:729–34.
3. Talungchit S, Buajeeb W, Lerdtripop C, Surarit R, Chairatvit K, Roytrakul S, et al. Putative salivary protein biomarkers for the diagnosis of oral lichen planus: a case-control study. BMC Oral Health 2018;18:42.
4. Al-Hashimi I, Schifter M, Lockhart PB, Wray D, Brennan M, Migliorati CA, et al. Oral lichen planus and oral lichenoid lesions: diagnostic and therapeutic considerations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103 Suppl:S25.e1-12.
5. Fitzpatrick SG, Hirsch SA, Gordon SC. The malignant transformation of oral lichen planus and oral lichenoid lesions: a systematic review. J Am Dent Assoc 2014;145:45–56.
6. Sugerman PB, Savage NW, Walsh LJ, Zhao ZZ, Zhou XJ, Khan A, et al. The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med 2002;13:350–65.
7. Cristaldi M, Mauceri R, Di Fede O, Giuliana G, Campisi G, Panzarella V. Salivary biomarkers for oral squamous cell carcinoma diagnosis and follow-up: Current status and perspectives. Front Physiol 2019;10:1476.
8. Blanco BA, Wolfgang CL. Liquid biopsy for the detection and management of surgically resectable tumors. Langenbecks Arch Surg 2019;404:517–25.
9. van Bilsen JHM, van den Brink W, van den Hoek AM, Dulos R, Caspers MPM, Kleemann R, et al. Mechanism-based biomarker prediction for low-grade inflammation in liver and adipose tissue. Front Physiol 2021;12:703370.
10. Zhou Z-T, Wei B-J, Shi P. Osteopontin expression in oral lichen planus: Osteopontin expression in oral lichen planus. J Oral Pathol Med 2008;37:94–8.
11. Lu R, Zhang J, Sun W, Du G, Zhou G. Inflammation-related cytokines in oral lichen planus: an overview. J Oral Pathol Med 2015;44:1–14.
12. Rhodus NL, Ho V, Miller CS, Myers S, Ondrey F. NF-kappaB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detect Prev 2005;29:42–5.
13. Pekiner FN, Demirel GY, Borahan MO, Ozbayrak S. Cytokine profiles in serum of patients with oral lichen planus. Cytokine 2012;60:701–6.
14. Abboud CS, Brandão EH da S, Cunha KRL, de Sousa Brito K, Gallo C de B, Molon AC, et al. Serum and salivary cytokines in patients with oral lichen planus treated with Photobiomodulation. Oral Dis 2023;29:1250–8.
15. Simark-Mattsson C, Bergenholtz G, Jontell M, Eklund C, Seymour GJ, Sugerman PB, et al. Distribution of interleukin-2, -4, -10, tumour necrosis factor-alpha and transforming growth factor-beta mRNAs in oral lichen planus. Arch Oral Biol 1999;44:499–507.
16. Kadry D, Rashed L. Plasma and tissue osteopontin in relation to plasma selenium in patients with psoriasis: Osteopontin and selenium in psoriasis. J Eur Acad Dermatol Venereol 2012;26:66–70.
17. Buback F, Renkl AC, Schulz G, Weiss JM. Osteopontin and the skin: multiple emerging roles in cutaneous biology and pathology. Exp Dermatol 2009;18:750–9.
18. Subraman V, Thiyagarajan M, Malathi N, Rajan ST. OPN -revisited. J Clin Diagn Res 2015;9:ZE10-3.
19. O’Regan AW, Nau GJ, Chupp GL, Berman JS. Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks. Immunol Today 2000;21:475–8.
20. Icer MA, Gezmen-Karadag M. The multiple functions and mechanisms of osteopontin. Clin Biochem 2018;59:17–24.
21. Denhardt DT, Noda M, O’Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001;107:1055–61.
22. Gebri E, Kiss A, Tóth F, Hortobágyi T. Salivary osteopontin as a potential biomarker for oral mucositis. Metabolites 2021;11:208.
23. Sodek J, Batista Da Silva AP, Zohar R. Osteopontin and mucosal protection. J Dent Res 2006;85:404–15.
24. Santarelli A, Mascitti M, Rubini C, Bambini F, Zizzi A, Offidani A, et al. Active inflammatory biomarkers in oral lichen planus. Int J Immunopathol Pharmacol 2015;28:562–8.
25. hang Y, Lin M, Zhang S, Wang Z, Jiang L, Shen J, et al. NF-kappaB-dependent cytokines in saliva and serum from patients with oral lichen planus: a study in an ethnic Chinese population. Cytokine 2008;41:144–9.
| Files | ||
| Issue | Vol 12, No 2 (Spring 2025) | |
| Section | Original Article(s) | |
| Keywords | ||
| Oral lichen planus Osteopontin Saliva | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Sharifi S, Hoseini E, Rahimi H, Lotfinia M. Salivary Osteopontin Was Associated with Lesion Size in Patients with Oral Lichen Planus. J Craniomaxillofac Res. 2025;12(2):93-99.
